Brief: Anika Therapeutics Completes Enrollment Of Phase III Clinical Study For Hyalofast
30/05/2023 22:39
May 30 (Reuters) - Anika Therapeutics Inc ANIK.O :
* ANIKA THERAPEUTICS INC-COMPLETED ENROLLMENT OF PIVOTAL
PHASE III
CLINICAL STUDY FOR HYALOFAST ON PATH TO ACHIEVING FDA APPROVAL
IN US
* ANIKA THERAPEUTICS INC-HYALOFAST HAS BEEN DESIGNATED AS
BREAKTHROUGH DEVICE BY FDA
* ANIKA THERAPEUTICS INC-TO BEGIN FILING MODULAR PMA IN 2024
WITH
FINAL MODULE FILING EXPECTED IN 2025
Source text for Eikon: ID:nGNX12H66t
Further company coverage: ANIK.O
((Reuters.Briefs@thomsonreuters.com;))